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Dysmenorrhea: Diagnostics 
Background  
1. Definitions  
o Cramping lower abdominal pain that occurs just before or during menstruation  
 Primary: painful menses in absence of underlying anatomic abnormality 
 Secondary: painful menses caused by underlying anatomic abnormality 
2. General information  
o Most common gynecologic problem in menstruating women  
3. See also Secondary dysmenorrhea 
Pathophysiology 
1. Pathology  
o Action of uterine prostaglandins  
 During endometrial sloughing, endometrial cells release prostaglandins 
 Prostaglandins stimulate myometrial contractions and ischemia 
o Women with most severe dysmenorrhea have highest levels of PGF2 alpha 
o Levels are highest during first 2 days of menses (when symptoms peak) 
o NSAIDs (which inhibit prostaglandin synthetase) relieve symptoms 
2. Incidence/prevalence  
o 20-90% of menstruating women (depending on measurement method) 
o Highest in adolescence  
3. Risk factors  
o Nulliparity 
o Earlier age at first menarche 
o Heavy/longer menstrual flow 
o Smoking 
o Depression/anxiety 
o Disruption of social networks 
o Attempts to lose wt 
o Age < 30 
o Low BMI 
o PMS 
o Sterilization 
o Sexual abuse 
o Obesity/alcohol use (controversial)  
4. Morbidity  
o Leading cause of short-term school absence in adolescent girls 
o Rates of absenteeism at work/school: 34%-50% 
o 600 million lost work hours/$2 billion lost productivity 
Diagnostics 
1. History  
o History is diagnostic 
o Usually 6-12 mo after menarche once cycles ovulatory/regular 
o Pain  
 Begins within hours of onset of menses  
 Peaks in first 1-2 d of cycle 
 Lasts 3-4 d 
 Commonly severe enough to miss school/work 
 Sharp, intermittent spasms, usually centered in suprapubic area 
 May radiate to back of legs/lower back 
o Commonly assoc symptoms  
 Nausea/vomiting 
 Diarrhea 
 Headache 
 Backache 
 Fatigue/malaise 
o Inquire about  
 Sexual hx 
 Exposure to STDs 
 Abnormal Pap smears 
 Contraceptive method 
 Pregnancy hx 
o Critical to rule out secondary causes of dysmenorrhea  
 See also Secondary dysmenorrhea 
o Failure to respond to NSAIDs should bring Dx into question 
2. Physical exam  
o General and abdominal exam sufficient in young adolescents who are not sexually 
active and have typical hx  
 Findings generally negative during non-menstrual phase of cycle 
 If pain is reproducible, it will be nonspecific and limited to midline 
o Pelvic exam if sexually active  
 STD screen 
3. Diagnostic testing  
o Usually none 
o Laboratory evaluation (nml in primary dsymenorrhea)  
 Usually not indicated 
 Do STD testing if sexually active and/or PID suspected 
 Potentially useful tests  
 CBC 
 ESR 
 UPT 
 Pap smear 
 Wet prep 
 Cervical cultures 
 UA 
 TSH 
o Diagnostic imaging (nml in primary dysmenorrhea)  
 Not routine 
 Used to rule out anatomic abnormalities if severe/refractory to usual 
therapy 
 Consider  
 Ultrasound 
 Hysteroscopy 
 Hysterosalpingogram (HSG) 
 Laparoscopy 
4. Diagnostic criteria  
o Dx usually made based on history and neg phys exam 
Differential Diagnosis 
1. Secondary dysmenorrhea  
o Suspect if Sx appear after many yrs of painless menses 
o Consider obstruction if onset during first 6 mo after menarche 
o Rule out if severe and/or refractory to usual therapy 
2. PMS  
o Pain generally restricted to breast tenderness, abdominal bloating  
 Sx do not include crampy lower abdominal pain 
o Sx begin before menstrual flow begins  
 Resolve shortly after flow begins 
3. Endometriosis  
o May present as progressive dysmenorrhea 
o Pain may be more generalized 
o Dyspareunia seen  
o Family hx likely  
 7% of cases have first-degree relative with laparoscopic Dx of 
endometriosis  
4. Extensive DDx  
o IBS 
o Chronic pelvic pain 
o Pregnancy 
o PID 
o Gonococcal cervicitis 
o Chlamydia genital infection 
o Gastroenteritis 
o UTI 
 
 
 
Goals 
1. Reduce/eliminate symptoms 
2. Restore patient's ability to function 
Pharmacotherapy  
1. NSAIDs (Grade 2A )  
o First-line treatment  
o Inhibit prostaglandin synthesis 
o 65-90% of cases will respond  
o Can take up to 3 mo for full effect to be seen 
o All classes are effective; try different class if inadequate response  
 Propionic acid derivatives (ibuprofen, naproxen)  
 Relatively inexpensive 
 Acetic acid derivatives  
 Aspirin not potent enough at usual dose 
 Enolic acid (oxicam) derivatives 
 Fenamates (mefenamic acid, tolfenamic acid, flufenamic acid, 
meclofenamate)  
 Some studies suggested may have better efficacy  
 Cox-2 inhibitors  
 Also effective but more expensive  
o Titrate dose to Sx 
o Scheduled or as needed 
o Relief usually seen within 30-60 min 
2. Acetaminophen less effective than NSAIDs in RCTs 
3. Narcotics occasionally indicated in refractory cases 
4. Oral contraceptives (Grade 2B )  
o Second-line therapy for most pts (first-line for women desiring contraception) 
o Mechanism of action  
 Reduction of menstrual flow 
 Suppression of ovulation 
o Up to 90% effective in some studies 
o Patches seem less effective than pills  
o Triphasics seem less effective than single formulation pills 
o Ring as effective as pills  
o Combination NSAIDs/oral contraceptives highly effective in refractory cases 
Suppression of Menses 
1. Extended cycles with combination OCPs  
o Withdraw Q 3 cycles, Q 5 cycles, or continuous oral contraception  
2. Depot Medroxyprogesterone  
3. Levonogestrel intrauterine system  
4. Etonogestrel-releasing contraceptive  
5. Danazol: rarely indicated  
6. Leuprolide acetate: rarely indicated  
Physical Modalities 
1. Possibly effective methods  
o Topical heat (Grade 2A ) 
o Exercise  
o Acupuncture/acupressure 
o High frequency transcutaneous electric nerve stimulation (TENS)  
2. Spinal manipulation not effective 
Nutritional Supplements 
1. Fish oil supplements (3 g daily) 
2. Low-fat vegetarian diet  
3. Thiamine supplementation (100 mg daily) 
4. Vitamin E supplementation (400 U daily)  
5. Pyridoxine alone or w/ magnesium 
6. Magnesium supplementation 
7. Herbal remedies  
o Toki-shakuyaku-san (Japanese herb)  
Psychological Counseling 
1. Helpful if psychological component suspected/refractory cases 
2. Pain mgmt training or relaxation might reduce Sx 
Surgical Therapy 
1. Insufficient evidence to recommend nerve interruption  
2. Hysterectomy rarely indicated 
Follow-up 
1. Return to office  
o If Sx not improved in 3 mo 
2. Refer to specialist  
o If combination NSAIDs/OCPs fail 
3. Admit to hospital  
o Generally not indicated for primary dysmenorrhea 
Prognosis 
1. Usually excellent pain relief w/ NSAIDs 
2. Sx may decline gradually w/ age after 25 yo. 
3. May persist throughout reproductive yrs 
Prevention 
1. Complete prevention not possible 
2. Partial prevention/symptom reduction  
o Proper nutrition 
o Regular exercise 
o Tobacco cessation 
o Minimal alchohol intake 
o Other generally good health habits 
Patient Education 
1. Handout found in Am Fam Physician 2005 Jan 15;71(2):292  
o http://www.aafp.org/afp/20050115/292ph.html  
2. Handout from Patient UK  
o http://www.patient.co.uk/showdoc/23068726/  
3. Handout from McKinley Health Center, University of Illinois  
o http://www.mckinley.illinois.edu/Handouts/menstrual_cramps.html  
4. Handout from Albemarle Pulmonary Medicine Associates, PA  
o http://www.apma-nc.com/httpdocs/PatientEducation/dysmenorrhea.htm  
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